{
    "name": "sutimlimab",
    "comment": "Rx",
    "other_names": [
        "sutimlimab-jome",
        "Enjaymo"
    ],
    "classes": [
        "Immunomodulators",
        "Monoclonal Antibodies",
        "Complement Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/enjaymo-sutimlimab-4000111",
    "pregnancy": {
        "common": [
            "No data are available on use in pregnant females to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Human immunoglobulin G (IgG) antibodies are known to cross the placental barrier; therefore, sutimlimab-jome may be transmitted from the mother to the developing fetus"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "IV administration of sutimlimab to pregnant monkeys during organogenesis at doses 2 to 3 times the maximum recommended human doses did not result in adverse effects on pregnancy or offspring development "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of sutimlimab-jome in human milk, its effects on breastfed children, or its effects on milk production",
            "Maternal IgG is known to be present in human milk",
            "Effects of local gastrointestinal exposure and limited systemic exposure in breastfed children to sutimlimab-jome are unknown"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to sutimlimab or inactive ingredients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Monitor for infusion-related reactions and interrupt if reaction occurs; discontinue infusion and institute appropriate supportive measures if signs of hypersensitivity reactions (eg, cardiovascular instability, respiratory compromise) occur",
                "May potentially increase the risk of developing autoimmune diseases such as systemic lupus erythematosus; monitor for signs and symptoms and manage medically",
                "Monitor for signs and symptoms of hemolysis such as elevated levels of total bilirubin or lactate dehydrogenase accompanied by decreased hemoglobin, or reappearance of symptoms such as fatigue, dyspnea, palpitations, or hemoglobinuria; consider restarting infusion if signs and symptoms of hemolysis occur after discontinuing"
            ],
            "specific": [
                {
                    "type": "Serious infections",
                    "description": [
                        "May increase susceptibility to serious infections, including infections caused by encapsulated bacteria such as",
                        " Neisseria meningitidis (a",
                        "ny serogroup)",
                        ", Streptococcus pneumoniae, ",
                        "and ",
                        "Haemophilus influenzae",
                        "Serious bacterial and viral infections were reported; infections included sepsis and respiratory and skin infections",
                        "Vaccination reduces but does not eliminate, risk of encapsulated bacterial infections;some infections may become rapidly life-threatening or fatal if not recognized or treated promptly",
                        "Inform patients of signs and symptoms of infections and steps to be taken to seek immediate care",
                        "Vaccinate patients for encapsulated bacteria according to the most current ACIP recommendations for patients with persistent complement deficiencies; revaccinate patients in accordance with ACIP recommendations",
                        "Immunize patients without a history of vaccination against encapsulated bacteria at â‰¥2 weeks before receiving initial dose ",
                        "If urgent therapy indicated in unvaccinated patient, administer vaccine(s) as soon as possible",
                        "If administered to patients with active systemic infections, monitor closely for signs and symptoms of worsening infection ",
                        "Consider treatment interruption in patients undergoing treatment for serious infection",
                        "Not studied in patients with chronic systemic infections such as hepatitis B, hepatitis C, or HIV"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Urinary tract infection",
            "percent": "38"
        },
        {
            "name": "Fatigue",
            "percent": "33"
        },
        {
            "name": "Dizziness",
            "percent": "29"
        },
        {
            "name": "Peripheral edema",
            "percent": "25"
        },
        {
            "name": "Respiratory tract infection",
            "percent": "25"
        },
        {
            "name": "Bacterial infection",
            "percent": "25"
        },
        {
            "name": "Arthralgia",
            "percent": "25"
        },
        {
            "name": "Hypertension",
            "percent": "23-25"
        },
        {
            "name": "Nausea",
            "percent": "25"
        },
        {
            "name": "Cough",
            "percent": "25"
        },
        {
            "name": "Headache",
            "percent": "21-23"
        },
        {
            "name": "Pyrexia",
            "percent": "21"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "21"
        },
        {
            "name": "Viral infection",
            "percent": "21"
        },
        {
            "name": "Abdominal pain",
            "percent": "21"
        },
        {
            "name": "Acrocyanosis",
            "percent": "18-21"
        },
        {
            "name": "Rhinitis",
            "percent": "18"
        },
        {
            "name": "Raynaud",
            "percent": "18"
        },
        {
            "name": "s phenomenon",
            "percent": "17"
        },
        {
            "name": "Infusion",
            "percent": null
        },
        {
            "name": "related reaction",
            "percent": null
        },
        {
            "name": "n",
            "percent": null
        }
    ]
}